Organigram Strikes A Deal to Acquire Aurora Cannabis
Organigram will acquire Aurora Cannabis for C$561 million (US$402 million), a 93% premium to Aurora's August 10 share price. Aurora shareholders will own 35% of the combined company. British American Tobacco will fund part of the deal. The acquisition aims to strengthen Organigram's position in the European cannabis market. Aurora's shares rose 21%, while Organigram's fell 2.6%.
How this was made
The 30-second read
Why it matters
A confirmed acquisition price with explicit premium metrics is likely to reprice Aurora immediately, while Curaleaf faces bid-contest risk and Organigram faces execution and funding scrutiny.
Market read
Deal terms and the hostile-bid resolution are immediate catalysts for the target, acquirer, and competing bidder.
What to watch
Regulatory and court approvals are still pending, and the article does not quantify financing terms beyond BAT’s stock purchase, leaving integration and funding execution risk.
Background
The article frames a contest between Organigram’s acquisition plan and Curaleaf’s hostile bid for Aurora, with talks reportedly first scooped in October.
Ticker impact
Aurora Cannabis is the acquisition target, with Organigram agreeing to buy it for C$7.80 per share, ending the hostile bid.
Likely upward pressure as the market prices the agreed premium, tempered by deal-approval uncertainty.
The article discloses a specific per-share offer price, premium metrics, and that approvals are still required, which directly drives target-stock repricing.
Organigram is the acquirer, agreeing to purchase Aurora for C$7.80 per share, a major strategic move into EU-GMP cultivation.
Near-term pressure or choppy trading is likely as investors weigh acquisition cost and execution risk.
The article notes Organigram shares fell about 2.6% on the halt ending, suggesting investors are discounting the deal despite strategic rationale.
Market effects
Signals consolidation in Canadian cannabis and strengthens the competitive position of EU-GMP certified cultivation assets.
Could shift sentiment across North American cannabis equities as deal premiums and hostile-bid outcomes reset expectations.
EU market access via GMP-certified facilities may influence cross-border cannabis supply and investment narratives.
Counterpoint
The agreed premium may not fully protect Aurora if approvals fail or if competing bids re-emerge, keeping downside tail risk for the target.
Key entities
- acquirerOrganigram
Agreed to acquire Aurora Cannabis for C$7.80 per share, positioning for EU cannabis market access via EU-GMP facilities.
- targetAurora Cannabis
Nasdaq-listed target receiving a C$7.80 per share offer, with shareholders to own about 35% of the combined company.
- hostile bidderCuraleaf
Launched and upsized a hostile bid for Aurora, now described as likely ending due to the Organigram deal.
- strategic backerBritish American Tobacco
Largest backer of Organigram’s deal funding, buying C$187.5 million of new stock to cover most of the cash portion.
